Alexandra Ladouceur

Dr. Ladouceur completed the MD/PhD program and her residency in core Internal Medicine at Université de Montréal, and her residency in Rheumatology at McGill University. Focusing on immune-related adverse events caused by the checkpoint inhibitors used in oncology, Dr Ladouceur then completed the Clinician Investigator Program at McGill University and the Centre Hospitalier Universitaire de Bordeaux. 

Dr. Ladouceur brings clinical expertise in the interface of rheumatology and oncology to McGill University, and a special interest in the rheumatic immune-related adverse events caused by the immune checkpoint inhibitors. She will collaborate locally and internationally in research projects in that field and actively participate in the recruitment of patients to the established Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) and Montreal Immune-Related Adverse Events (MIRAE) cohorts.